Dopamine agonist treatment of Tourette disorder in children: Results of an open-label trial of pergolide

Movement Disorders

Volumn 12, Issue 3, 1997, Pages 402-407

  Lipinski, Joseph F ^a   Sallee, Floyd R ^a   Jackson, Cherry ^a   Sethuraman, Gopalan ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dopamine agonists; Pergolide; Restless legs syndrome; Tourette syndrome

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SCHOOL CHILD;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PERGOLIDE; PILOT PROJECTS; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TOURETTE SYNDROME;

EID: 0030926656     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120320     Document Type: Article

References (35)

1. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46: 722-30.
2. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 1988;145:621-4.
3. Silva R, Magee H, Friedhoff A. Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette's disor-der. J Child Adolesc Psychopharmacol 1993;3:137-44.
4. Leckman JF, Cohen DJ. Clonidine treatment of Gilles de la Tourette'e syndrome. Arch Gen Psychiatry 1991;48:324-8.
5. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebocontrolled study with clonidine and desipramine. Pediatrics 1995;95:74-81.
6. Kurlan R, Como P, Deeley C, McDermott M, McDermott MP. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol 1993; 16:167-72.
7. Singer HS. Pathobiology. In: Kurlan R, ed. Handbook of Tourette's syndrome and other related tic and behavioral disorders. New York: Marcel Dekker, 1993:267-88.
8. Pauls DL, Leckman JF, Cohen DJ. Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering. J Am Acad Child Adolesc Psychiatry 1993;32:1044-50.
9. Müller N, Voderholzer U, Kurtz G, Sträube A. Tourette's syndrome associated with restless legs syndrome and akathesia in a family, Acta Neural Scand 1994;89:429-32.
10. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1995;17:739-43.
11. Walters AS, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the "nightwalkers" survey. Neurology 1996;46:92-5.
12. O'Keeffe ST. Restless legs syndrome. Arch Intern Med 1996;156:243-8.
13. Walters AS, International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord 1995;5:634-42.
14. Walters AS, Picchietti DL, Ehrenberg BL, Wagner ML. Restless legs syndrome in childhood and adolescence. Pediatr Neurol 1994;11:241-5.
15. Picchietti DL, Walters AS. Attention-deficit hyperactivity disorder and periodic limb movement disorder in childhood. Sleep Res 1994;23:303.
16. Montplaisir J, Godbout MA, Boghen D, Dechamplain J, Young SN, Lapierre G. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985;35:130-4.
17. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: A double-blind, controlled study. Neurology 1988;38:1845-8.
18. Walters AS, Hening W, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neural 1988; 24:455-8.
19. Feinberg M, Carroll BJ. Effects of dopamine agonists and antagonists in Tourette's disease. Arch Gen Psychiatry 197;36:979-85.
20. Chambers WJ, Puig-Antich J, Hirsch M, et al. The assessment of affective disorders in children and adolescents by semistructured interview. Arch Gen Psychiatry 1985;42:696-702.
21. Swanson JM, ed. School-based assessments and interventions for ADD students. Irvine: KC Publishing, 1992.
22. Walters AS, Hening WA, Chokroverty S. Review and videotape recognition of idiopathic restless legs syndrome. Mov Disord 1991;6:105-10.
23. Harcherik DF, Leckman JF, Detlor J, Cohen DJ. A new instrument for clinical studies of Tourette's syndrome. J Am Acad Child Psychiatry 1984;23:153-60.
24. 4
25. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen D. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-73.
26. Goodman WK, Price LH, Rasmusson SA, et al. The YaleBrown Obsessive Compulsive Scale (Y-BOCS): Part 1. I. Development, use and reliability. Part 2. Validity. Arch Gen Psychiatry 1989;46:1006-16.
27. Guy W. ECD EUassessment manual for psychophannacology. Washington, D.C.: U.S. Department of Health, Education, and Welfare, 1976:634-7.
28. Sallee FR, Dougherty D, Sethuraman G, Vrindavanam N. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette syndrome. Biol Psychiatry (in press).
29. Berg MJ, Ebert B, Willis DK, Host T, Fincham RW, Schottelius DD. Parkinsonism-drug treatment: part II. Drug Intell Clin Pharm 1987;21:167-72.
30. Singer HS, Buffer IJ, Tune LE, Seifert WE, Coyle JT. Dopa-minergic dysfunction in Tourette syndrome. Ann Neural 1982;12:361-6.
31. White FJ, Wang RY. Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmantal area: microiontophoretic studies. J Pharmacol Exp Ther 1984;231:275-80.
32. Lehmann J, Briley M, Langer SZ. Characterization of dopamine autoreceptor and 3H-spiperone binding sites in vitro with classical and novel dopamine receptor agonists. EurJ Pharmacol 1983;88:ll-26.
33. Fuller RW, Clemens JA. Pergolide: a dopamine agonist at both D1 and D2 receptors. Life Sci 1991;49:925-30.
34. Fuller RW, Clemens JA, Kornfeld EC, Snoddy HD, Smalstig EB, Bach NJ. Effects of (8Beta)-8-((methylthio)methyl)-6propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci 1979;24:375-82.
35. Lemberger L, Crabtree RE, Callaghan JT. Pergolide, a potent long-acting dopamine-receptor agonist. Clin Pharmacol Ther 1980;27:642-51.